CN101137905A - 使用反应化学的侧流装置 - Google Patents
使用反应化学的侧流装置 Download PDFInfo
- Publication number
- CN101137905A CN101137905A CNA2006800081002A CN200680008100A CN101137905A CN 101137905 A CN101137905 A CN 101137905A CN A2006800081002 A CNA2006800081002 A CN A2006800081002A CN 200680008100 A CN200680008100 A CN 200680008100A CN 101137905 A CN101137905 A CN 101137905A
- Authority
- CN
- China
- Prior art keywords
- analyte
- chromogen
- aryl
- lateral flow
- detection zone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012491 analyte Substances 0.000 claims abstract description 60
- 238000001514 detection method Methods 0.000 claims abstract description 45
- 239000012528 membrane Substances 0.000 claims abstract description 37
- 238000003556 assay Methods 0.000 claims abstract description 14
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 62
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 2
- 210000003756 cervix mucus Anatomy 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000005001 aminoaryl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 230000002000 scavenging effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 239000000523 sample Substances 0.000 description 21
- 239000000020 Nitrocellulose Substances 0.000 description 19
- 229920001220 nitrocellulos Polymers 0.000 description 19
- OAZWDJGLIYNYMU-UHFFFAOYSA-N Leucocrystal Violet Chemical compound C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 OAZWDJGLIYNYMU-UHFFFAOYSA-N 0.000 description 17
- 239000012530 fluid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000975 dye Substances 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000013016 damping Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- -1 amino, hydroxyl Chemical group 0.000 description 4
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 229910044991 metal oxide Inorganic materials 0.000 description 4
- 150000004706 metal oxides Chemical class 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 108010089254 Cholesterol oxidase Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 201000005485 Toxoplasmosis Diseases 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- JUQPZRLQQYSMEQ-UHFFFAOYSA-N CI Basic red 9 Chemical compound [Cl-].C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=[NH2+])C=C1 JUQPZRLQQYSMEQ-UHFFFAOYSA-N 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000692870 Inachis io Species 0.000 description 2
- 102000019298 Lipocalin Human genes 0.000 description 2
- 108050006654 Lipocalin Proteins 0.000 description 2
- KEECCEWTUVWFCV-UHFFFAOYSA-N N-acetylprocainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1 KEECCEWTUVWFCV-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 229940052223 basic fuchsin Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- OBRMNDMBJQTZHV-UHFFFAOYSA-N cresol red Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 OBRMNDMBJQTZHV-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 description 2
- 150000004692 metal hydroxides Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002161 passivation Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000272165 Charadriidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- ZKNARUVAUOSLGV-UHFFFAOYSA-N N1N=CC=CC=C1.C1=CC=CC=C1 Chemical compound N1N=CC=CC=C1.C1=CC=CC=C1 ZKNARUVAUOSLGV-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical group ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- GLLRIXZGBQOFLM-UHFFFAOYSA-N Xanthorin Natural products C1=C(C)C=C2C(=O)C3=C(O)C(OC)=CC(O)=C3C(=O)C2=C1O GLLRIXZGBQOFLM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940098184 amytal Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001001 arylmethane dye Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- RXQCGGRTAILOIN-UHFFFAOYSA-N mephentermine Chemical compound CNC(C)(C)CC1=CC=CC=C1 RXQCGGRTAILOIN-UHFFFAOYSA-N 0.000 description 1
- 229960002342 mephentermine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001003 triarylmethane dye Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/805—Test papers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/97—Test strip or test slide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/805—Optical property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/81—Tube, bottle, or dipstick
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
本发明提供用于检测测试样品中被分析物的存在或量的侧流测定装置,其中该侧流测定装置具有与芯吸垫连通的多孔膜。该多孔膜具有有发色体的检测区,该发色体经构建成与被分析物或二次触发剂或来自被分析物和触发剂生成剂的反应产物起化学反应以产生视觉上可觉察的信号。其他发色体区可位于第一发色体区下游以产生不同颜色的信号。清除区可包括在发色体区之间以在不产生视觉上可觉察的信号的情况下与被分析物起反应来减少信号。
Description
发明背景
本发明涉及侧流装置在检测被分析物含量中的用途。
流通(flow through)或侧流(lateral-flow)测定已越来越常用于多种被分析物。这些装置根据流动相(如体液)的毛细流动原理通过多孔固体支撑膜来工作。传统侧流测试使用在所关注的被分析物存在的情况下会在预定结合部位被捕获或结合的染色或金属纳米颗粒。被分析物的浓度增加引起在这些结合部位内纳米颗粒的密度增加。因此被分析物的量可通过定量测定纳米颗粒的数目来确定。这通常需要使用读数器,增加了测试的复杂性和成本。
仍需要无需读数器的快速、定量测试。
发明概述
根据本发明的一个实施方案,公开了一种用于检测测试样品中被分析物的存在或量的测定装置。所述测定装置包括吸水膜,在该吸水膜中发色体(对可为被分析物本身的被分析物触发剂或二次触发剂或来自被分析物和触发剂生成剂的反应产物具有特异性)的多个区域以精确的模式固定。设计这些发色体区中的每一个以通过调整发色体对触发剂的反应性或反应全有或全无的方式呈现。发色体产生视觉上可察觉的变化,且通过增加区域数可编码(encode)任何所要的触发剂浓度的量或范围。
这类区域不必含有相同发色体。例如,如果希望传达被分析物含量在可接受、边界或较高范围内,则接续区中的发色体可分别产生绿色、黄色和红色。
如果需要,则可将清除区插在反应区之间。这些清除区含有与触发剂反应但不产生可见变化的反应物,从而有效减少样品中触发剂的量。
本发明的其他特征和方面在下文中更详细地论述。
附图简述
图1为本发明的侧流测定装置的一个实施方案的透视图。
图2为含有清除区的本发明的侧流测定装置的一个实施方案的透视图。
发明详述
本文所用的术语“被分析物”通常是指有待检测的物质。例如,被分析物可包括抗原物质、半抗原、抗体及其组合。被分析物包括但不限于毒素、有机化合物、蛋白质、肽、微生物、氨基酸、核酸、激素、类固醇、维生素、药物(包括那些出于治疗目的而施用的药物以及那些出于非法目的而施用的药物)、药物中间体或副产物、细菌、病毒颗粒、酵母、真菌、原生动物和上述物质中任一种的代谢产物或抗体。一些被分析物的具体实例包括铁蛋白;肌酸酐激酶MB(CK-MB);地高辛;苯妥英;苯巴比妥(phenobarbitol);卡马西平(carbamazepine);万古霉素;庆大霉素;茶碱;丙戊酸;奎尼丁;促黄体生成激素(LH);促卵泡激素(FSH);雌二醇、黄体酮;C-反应性蛋白;脂质运载蛋白(lipocalin);IgE抗体;细胞因子;维生素B2微球蛋白;糖化血红蛋白(Gly.Hb);皮质醇;毛地黄毒苷;N-乙酰普鲁卡因胺(NAPA);普鲁卡因酰胺;对风疹的抗体,例如风疹IgG和风疹IgM;弓形体病的抗体,例如弓形体病IgG(Toxo-IgG)和弓形体病IgM(Toxo-IgM);睾丸激素;水杨酸酯;醋氨酚;乙型肝炎病毒表面抗原(HBsAg);乙型肝炎核心抗原的抗体,例如抗乙型肝炎核心抗原IgG和IgM(Anti-HBC);人类免疫缺陷病毒1和2(HIV1和2);人类T细胞白血病毒1和2(HTLV);乙型肝炎e抗原(HBeAg);乙型肝炎e抗原的抗体(Anti-HBe);流感病毒;促甲状腺激素(TSH);甲状腺素(T4);总三碘甲腺原氨酸(Total T3);游离三碘甲腺原氨酸(Free T3);癌胚抗原(CEA);脂蛋白、胆固醇和甘油三酯;和甲胎蛋白(AFP)。滥用的药物和受控制的物质包括但不限于安非他明;甲苯丙胺;巴比妥酸盐,例如异戊巴比妥、司可巴比妥、戊巴比妥、苯巴比妥和巴比妥;苯二氮杂草,例如利眠宁和安定;大麻素,例如印度大麻和大麻;古柯碱;芬太尼;LSD;安眠酮;鸦片剂,例如海洛因、吗啡、可待因、氢吗啡酮、氢可酮、美沙酮、氧可酮、氧吗啡酮和鸦片;苯环利定;和丙氧芬。其他可能的被分析物可描述于美国专利第6,436,651号中。
本文所用的术语“测试样品”通常是指被怀疑含有被分析物的材料。例如,测试样品可包括直接从来源获得的材料,以及使用一些技术预处理的材料,这些技术例如但不限于过滤、沉淀、稀释、蒸馏、混合、浓缩、干扰成分的钝化、加入试剂、溶胞作用(lysing)等等。测试样品可来自生物来源,例如生理流体,包括血液、间质液、唾液、眼晶状体液、脑脊髓液、汗液、尿液、乳液、腹腔积液、粘液、滑液、腹膜液、阴道液、羊膜液等等。除了生理流体之外,可使用其他液体样品,例如水、食品等等。另外,被怀疑含有被分析物的固体材料也可用作测试样品。
通常,本发明涉及用于检测测试样品中被分析物的存在或量的侧流测定装置。
在常规侧流方法中,样品通常施加在固定结合颗粒的位置的上游,从而使样品可帮助再悬浮颗粒以使测试进行。然而,相反地,本发明并不使用固定的结合颗粒,而是使用反应化学以指示被分析物的存在。本发明测定装置包括吸水膜,在该吸水膜中发色体(对可为被分析物本身的被分析物触发剂或二次触发剂或来自被分析物和触发剂生成剂的反应产物的具有特异性)的多个区域以精确的模式固定。
反应化学是指发色体与被分析物之间的化学反应。可根据所要检测的具体被分析物和所要显示的具体可见信号选择数种发色体。
理想的是,不同区域中的发色体可以相同的反应机制与触发剂反应而产生不同的颜色。优选这类颜色变化的发色体来自相同的染料种类而因其结构和官能团的变化产生不同的颜色。
特别适用于本发明的一类发色体为芳基甲烷染料,例如二芳基甲烷、三芳基甲烷等等。
例如,三芳基甲烷可具有以下通用结构:
其中R、R'和R″独立地选自被取代或未被取代的芳基,例如苯基、萘基、蒽基等。所述芳基例如可被例如以下官能团取代:氨基、羟基、羰基、羧基、磺酸基、烷基和/或其他已知官能团。
用于医学诊断(包括葡萄糖)的普通检测方法涉及在检测之前被分析物向过氧化氢的转化。这种方法在本领域中已知且例如在美国专利4,973,549中指出。一般说来,过氧化物将作为胆固醇酯酶和胆固醇氧化酶的偶合酶促反应的副产物而产生。反应调合物应包括提供与被分析物反应以产生可检测量的过氧化物所必需的所有适当的酶、辅因子、底物或其他添加剂。例如,在胆固醇的情况下,胆固醇酯酶和胆固醇氧化酶的浓度通常各自为约0.1-100IU(国际单位),更通常各自为约0.5-10IU。三芳基甲烷指示剂(例如无色结晶紫)的量通常应在100pmol-1000pmol范围内,但由于有足够的非限速量的催化剂,例如辣根过氧化物、氯化血红素、血红蛋白或细胞色素C,三芳基甲烷指示剂的量通常为约250pmol。另外,应提供足够的底物和辅因子免得限制速度。一般来说,各组分的浓度不会超过约1摩尔浓度,通常不超过0.5摩尔浓度。缓冲液一般应具有约6-10,通常6.5-9范围内的pH值,一般来说,缓冲液的浓度应为约50-500mmol。可使用各种缓冲液,包括但不限于Tris、磷酸盐、碳酸盐和MOPS(4-吗啉丙磺酸)。应选择所使用的特定缓冲液以使由缓冲液引起的不利影响减至最小。其他添加剂可包括用以获得所要离子强度的盐、稳定剂、杀生物剂和例如清洁剂和胆汁盐及其衍生物的增溶剂。
一种合适染料的实例为无色结晶紫染料类,如下文所示,其包括结晶紫、孔雀绿、碱性品红及甲酚红。这类染料可在经受涉及例如过氧化氢的氧化触发剂的氧化还原过程时改变颜色。这种颜色改变反应可在反应通过使用例如过氧化氢氧化酶(HRP)、细胞色素C等的酶催化剂进行时大大加速。如上文所讨论,过氧化氢触发剂可在样品自样品施加区流动且通过触发剂生成区时在触发剂生成区中产生。
在过氧化氢和催化剂存在下,无色结晶紫在硝化纤维上产生可观察到的信号。最终产物(结晶紫)属于阳离子型三芳基甲烷染料类,其对纤维素材料和蛋白质材料具有亲和力,从而大部分染料将保持固定在适当位置且不易被除去。这种性质已由美国联邦调查局(FBI)采用,例如用于增强鞋和指纹印记证据。这种性质具有重要性,因为侧流装置根据流动相(例如有待测试的体液)的毛细流动通过多孔固体支撑膜的常规原理操作。因此,希望指示剂一旦被置于支撑物上,则其将不被分配到流动相中,也不随流动相被带走,不然将使信号减弱。指示剂无色结晶紫(LCV)具有这种性质且其为无色的,进一步增强其合意性。
结晶紫
孔雀绿
碱性品红
甲酚红
如果需要,则可将清除区插在反应区之间。这些清除区包含与触发剂反应但不产生可见变化或产生可物理阻挡的可见变化从而有效减少样品中触发剂的量的反应物。
根据被分析物的性质,可选择许多材料用于清除目的。例如,在检测胆固醇的情况下,清除区必须能消耗在两个检测区之间的过量过氧化氢以在每个区域获得精确的检测。用于这个目的的合适材料包括过氧化氢分解催化剂和具有瞬间过氧化氢络合性质的活化金属中心。
清除剂区应为无色的,然而,可使用发色体,条件是将清除剂区遮蔽使其不被使用者看到或所使用的指示剂随流动相流动。例如,Amplex red(一种已知的过氧化氢指示剂)对于硝化纤维具有微弱亲和力。因此,将这种材料在硝化纤维的检测区之间划条带,产生一旦测试完成不可见的移动清除区。因为过量过氧化氢正被Amplex red清除,所以产生荧光红色,其随溶剂前沿迁移,使最初的条带区域无色。
过氧化氢分解催化剂的实例可选自低氧化态金属氧化物,例如氧化锰MnO、CoO和NiO。混合的金属氢氧化物和金属氧化物(例如受让给Kimberly-Clark的美国专利申请6,350,543指出的那些混合的金属氢氧化物和金属氧化物)也适于本发明。
金属氧化物可通过油墨制剂或糊剂施加在所要清除区上的膜条带之上。过氧化氢清除或分解金属络合物的实例可选自文献中描述的许多已知与过氧化氢起反应的有机金属化合物。这类络合物的一个具体实例可见于A.F.M.Mokhlesur Rahman等人(InorganicChemistry(无机化学),2004,43(24),7558-7560)中且络合物的结构如下所示:
其中R1-R4为烷基,例如甲基和乙基。
一方面,在检测区之间清除区的使用与样品中被分析物的总量相互关联。理想的是,清除区中清除剂的总量应小于被分析物的总量,但等于检测区中被分析物总量减去染料总量的量。另一方面,根据检测区的灵敏性,不同检测区中的装载量可相同或不同。
在一个实施方案中,本发明为用于胆固醇的侧流装置,其具有五个反应区。第一区域、第三区域和第五区域对应于小于200mg/dL总胆固醇、200-239mg/dL总胆固醇和大于240mg/dL总胆固醇的当前医学指标。设计这些区域中的每一个使其具有全有或全无反应(allor none response);简而言之,其将仅指示胆固醇或其衍生物(过氧化物为最便利的选择,因为其为胆固醇氧化酶催化作用的副产物)是否透过该区域。设计第二反应区和第四反应区用以破坏过量的胆固醇或其衍生物。
例如,假定将包含250mg/dL胆固醇的样品施加到装置中且如上文所讨论使其转化为过氧化物,则过氧化物穿过侧流膜直至其到达第一区域(指示小于200mg/dl)。此时,第一区域将变为绿色且过量的过氧化物将进入第二区域(清除区)。过氧化物将被清除,使得仅仅大于200mg/dL的量的胆固醇进入第三区域。当过氧化物进入第三区域时,该区域变为黄色,指示胆固醇在200mg/dl与239mg/dl之间。在第四区域(另一清除区),对应于200-239mg/dL胆固醇的过氧化物被清除。最后,随着样品进入第五区域,检测区变为红色,指示胆固醇大于240mg/dl。因此,对于胆固醇含量为250mg/dL的情形,总体结果是出现三条带:绿色、黄色和红色。
该装置通常利用具有样品施加区和检测区的多孔膜。根据有待检测的被分析物,可存在任选的触发剂生成区。
检测区具有对待测试被分析物具有特异性的发色体。样品施加区位于装置末端发色体上游。触发剂生成区在样品施加区和检测区之间。芯吸垫在装置下游端上,与多孔膜的与样品施加区相对端液体连通。在使用时,将样品施加在样品施加区中,且一段时间之后,样品由于芯吸垫的毛细作用而朝检测区方向上移动。
所述装置可任选包括插有控制区(control zone)的清除区。清除区的目的是用以减少样品中被分析物的量。合适的清除区反应物将取决于所测试的被分析物,但应能够在不产生视觉上可观察到的信号的情况下与被分析物起反应。
可将检测区染料和清除区材料同时或分别施加到多孔膜上。对于同时施加来说,化学品可通过使用划带器或印刷机施加。对于分别施加来说,检测区和清除区可分别产生,随后在施加试剂之后层合在一起。单独的检测区垫或清除区垫可例如由多种膜材料(例如纤维材料、尼龙膜、硝化纤维膜、机械膜(mech membrane)、纤维素纸等)制造。
与选择的染料和材料无关,可使用各种技术中的任一种来施加这些染料和材料到多孔膜上。染料和材料可直接施加到膜上或在施加之前首先形成溶液。可使用各种溶剂形成溶液,例如但不限于乙腈、二甲亚砜(DMSO)、甲醇、乙醇、二甲基甲酰胺(DMF)和其他极性有机溶剂。溶液中化学染料的量可为约0.001到约1mg/ml溶剂,且在一些实施方案中,为约0.01到约0.1mg/ml溶剂。可使用公知的技术将溶液涂覆到多孔膜上,随后干燥。
在一个实施方案中,可将清除垫层合在两个检测区之间。为了有助于流体通过层合的清除垫,可在两个检测区之间形成通道。例如,这种通道可通过在检测区之间物理地划掉膜或使用溶剂来溶解膜材料(例如使用甲醇以溶解硝化纤维膜)而形成。
参考图1,将更详细地描述可形成的侧流测定装置20的一个实施方案。应注意到,术语“侧流”意欲描述且不是限制,因为可以其他方式构建具有相同作用的装置。在不偏离本发明的精神的情况下,例如使用与本发明相同的原理可容易地想象径向(radical)或垂直(vertical)流动装置。如所示,装置20包含任选由刚性材料24支撑的多孔膜22。多孔膜22具有检测区(或线)30。
一般说来,多孔膜22可由能使检测探针通过的各种材料中的任一种制造。例如,用于形成多孔膜22的材料可包括但不限于天然的、合成的或经合成性改性的天然材料,例如多糖(例如纤维素材料,如纸和纤维素衍生物,例如醋酸纤维素和硝化纤维);聚醚砜;聚乙烯;尼龙;聚偏二氟乙烯(PVDF);聚酯;聚丙烯;二氧化硅;无机材料,例如钝化的氧化铝、硅藻土、MgSO4或其他均匀地分散在多孔聚合物基质中的无机细分散材料,所述聚合物例如为氯乙烯、氯乙烯-丙烯共聚物和氯乙烯-醋酸乙烯共聚物;布,天然的(例如棉花)和合成的(例如尼龙或人造纤维);多孔凝胶,例如硅胶、琼脂糖、葡聚糖和明胶;聚合物薄膜,例如聚丙烯酰胺;等等。在一个特别的实施方案中,多孔膜22由硝化纤维和/或聚醚砜材料形成。应当理解的是,术语“硝化纤维”是指纤维素的硝酸酯,其可以是单独的硝化纤维或硝酸和其他酸的混合酯,其他酸例如具有1到7个碳原子的脂族羧酸。合适的膜包括来自Billerica,MA.,USA的Millipore Corporation的硝化纤维膜HF075和HF120。
装置20还可含有芯吸垫26。芯吸垫26通常接受已迁移通过整个多孔膜22的流体。如本领域中所公知,芯吸垫26可有助于促毛细管作用和流体流过膜22。
为了开始进行测试样品中被分析物的检测,使用者可直接将测试样品施加、接触或沉积到施加区28上。样品穿过多孔膜22到达检测区30且如果所期望的分析物存在,则见到可见信号。
再次参考图1,测定装置20含有在其内固定有能够与被分析物起化学反应的第一发色体的检测区30。被分析物的结合产生被分析物存在的可检测的指示且该指示为可见的。含被分析物的样品可在装置中继续向前行进,直至其到达第二检测区32的第二发色体,其再次产生视觉上可检测的颜色改变。检测区通常可提供任意数目的不同检测区使得使用者可更好地测定测试样品中特定被分析物的浓度。每个区域可含有相同的发色体,或可含有用于捕获多种被分析物的不同发色体。例如,检测区30可包括两个或多个不同的检测区(例如线、点等)。检测区可在大体垂直于测试样品流过测定装置20的流动方向上以线的形式排列。同样地,在一些实施方案中,检测区可在大体平行于测试样品流过测定装置的流动方向上以线的形式排列。
图2表示包括清除区的实施方案。清除区40、42位于检测区30、32、34之间。这个实施方案还包括在样品施加区28与第一检测区32之间的触发剂生成区50。
构造中包括两个过氧化氢检测区的本发明的一个实施方案如下详述。
实施例1:
将25mm宽×30cm长的硝化纤维条带(Millipore Corp.,SHF1200425)层合到60mm×30cm Millipore背卡(HF000MC100)的25mm宽区域,使15mm背卡暴露于硝化纤维条带一侧且其余(20mm)在另一侧。无色结晶紫(LCV,Hiton-Davis Chemical Co.,Cincinnati,OH)指示剂溶液通过混合1.4mM LCV在0.5%盐酸中的溶液与1ml1.4mg/mL马肝细胞色素C(Sigma-Aldrich Corp,St.Louis,MO)来制备。在使用前使所得溶液在室温下平衡1小时。随后,将HPLC级甲醇(Sigma-Aldrich Corp.)加到共混物中,直到LCV的最后浓度达到3%体积。使用装备有双非接触型喷雾头的KinematicAutomation(Twain Harte,CA)Matrix 1600试剂分配体系(喷射参数为0.9μL染料/cm且划条带速率为7cm/s)将LCV溶液喷射到上述硝化纤维上。条带离硝化纤维膜底缘大约10和15mm。随后,将玻璃纤维/纤维素混合芯吸垫(CF6,Whatman,Clifton,NJ)施加到暴露的背卡15mm宽区域,以便与吸水硝化纤维膜重叠1-1.5mm。将卡片在0湿度环境中在37℃下干燥1小时。干燥之后,使用剪刀将背卡的未层合部分(即约20mm)除去且丢弃。最后,将目前得到的大约40mm宽×30cm长的层合卡片切成4mm宽条带(Kinematic Automation Matrix2360程控剪切)且置于含有干燥剂小袋的塑料袋(MiniPax(R),MultisorbTechnologies,Inc.,Buffalo,NY)中,从而使其保持干燥。应注意到每个反应区含有250皮摩尔LCV,已知LCV在催化剂存在下以1∶1化学计量反应。因此,第一检测区在测试溶液含有过氧化氢时被触发;然而,第二检测区LCV条带仅在溶液含有大于250皮摩尔过氧化氢的情况下才被触发。
为了测试该装置,使所有反应均在室温、周围室内条件下如下进行:
制备十二份两倍连续稀释的过氧化氢(Amplex Red胆固醇测定盒的组分D,A12216,Molecular Probes Inc.,Eugene,OR)在100mM磷酸钠缓冲液(pH为5.88的反应缓冲液)中的溶液。随后,吸取1μL所得溶液中的每一种分别到距12个测试条带底缘的3mm处。通过将条带置于40μLpH为5.88的100mM磷酸钠缓冲液中,开始测试。反应顺畅地进行,直到所有缓冲液均被测试条带吸收,用时大约5分钟。
LCV到结晶紫的转化使用Hewlett Packard ScanJet 5470C数字扫描仪量化。简而言之,扫描仪使用出厂缺省曝光设定设置在1200DPI的灰阶模式(grayscale mode)。扫描数据保存为未压缩的TIFF格式文件,随后用Adobe Photoshop CS打开这些文件且转变为灰阶图像。虽然数据是以灰阶图像形式收集,但TIFF文件的位标记(bit flag)妨碍其直接输进量化软件包。随后,由于输进Image Quant 5.2(Amersham Biosciences,Piscataway,NJ)(用于量化的图像分析软件)时发生自动转化,将灰阶值转化。这样有效地保存了每个文件的原始内容。随后,将文件输进Image Quant 5.2,在软件中产生包含显色带的感兴趣矩形区(ROI)。对于每一个剩余带以及背景来说,产生该ROI的精确副本。应注意到未显色膜的不同区域的随机测量结果彼此在3%内(数据未展示),因此选择背景ROI的位置使其位于两个条带之间。软件随后计算每个区域的量(volume)(在整个ROI上各像素强度的和)。每个ROI通过自每个条带减去背景ROI值来校正。浓度最高的过氧化物溶液设为100,将每个条带的数据绘制为相对过氧化氢浓度的函数。
出乎意料且与过氧化氢浓度无关的是,两个反应区颜色的改变程度相同。这种情况的出现的原因,或者可能是由于反应动力学太缓慢以致于在过氧化氢通过条带指示剂区时不能将其有效捕获,或过氧化物溶液沿带绕行(travel around the band)。为了确定后者的可能性,我们用含1滴绿色食用染料(McCormick&Company,Inc.,Sparks,MD)示踪1ml反应缓冲液。随后,将侧流条带固定到Digital Blue QX5Computer Microscope(Digital Blue,Hayward,CA)的载物台上。设定显微镜以640×480象素分辨率和每秒15帧收集数字视频。开始收集数据之后,使用普通实验室移液管将10μL绿色染料溶液施加到硝化纤维底缘。
收集视频直到硝化纤维基料被绿色染料饱和。当观察视频的连续镜头时,发现在第一LCV区之前,溶剂前沿几乎平直地穿过整个膜。最初的条带渗透导致在前部几乎没有变化。然而,当条带区域变湿近三分之一时,溶剂外缘开始沿硝化纤维边缘向上比穿过中心迁移更快,形成U形溶剂前沿。条带湿润进一步变慢,但反应缓冲液继续沿边缘向上移动,直至其到达带末端。此时,在带上方的侧向迁移继续向条带中心进行。在侧向迁移边缘前部在第一反应区之上的条带中心处相遇之后,湿润以向上和向下的方式继续。因此,使第一反应区部分湿润,将其包裹,随后最后彻底地从上到下湿润。第二反应区受相同处理。
这种现象在测流文献中公知且已称为“潜式效应(submarining)”。一般来说,这由膜表面能的巨大差别产生。在这种情况下,干燥的染料产生大大不同于其余膜的疏水斑。为了弥补这个问题,必须使得表面能匹配且最通常使用本领域通常已知的许多技术经后阻挡步骤来完成。关于调整硝化纤维膜的其他资料可见于http://www.devicelink.com/ivdt/archive/99/05/002.html中。
本领域中有经验的人能通过优化划条带条件减轻潜式效应问题。另外,可能需要优化催化剂的浓度,以便使用通常用于本领域中的许多技术促进有效捕获和催化指示剂区中的过氧化氢以达到最佳测试,在该测试中特定、预定剂量的过氧化氢(基于反应区内LCV的浓度)仅在底部LCV条带中导致颜色变化。
实施例2:
首先将Whatman滤纸(CAT号1003110,切成31.75×31.75mm大小)用0.1g/ml Hybrane-32树状三聚物(DSM Corporation)浸泡约3分钟,随后用15ml 13.3mg/ml FeCl2水溶液浸泡3分钟。随后将所得黄色滤纸用水充分洗涤,随后在37℃下干燥。随后将干燥的滤纸切成用于清除过氧化氢的3mm×4mm的清除垫。
为了证实过氧化氢在两个发色体带之间清除,使用与实施例1中所制备的测试条带相同的测试条带,装配成具有两个发色体带和一个清除带的条带。
将3mm×4mm的清除垫置于两个发色体带之间的通道之上,用胶带将其固定,且通过将条带末端置于包含2μL25mM过氧化氢溶液的40μL100mM磷酸钠缓冲液(pH5.88)中来开始测试。对于第一带观察到强烈的颜色改变,且第二带仅展示微弱的颜色改变。在相同条件下,采用没有清除剂的对照清除垫时,两个发色体带都发生强烈的颜色改变。
虽然已经根据本发明的具体实施方案详细地描述了本发明,但本领域技术人员应当理解的是,在通过上述内容了解了本发明之后,可以容易地构想出这些实施方案的替换物、变体和等价物。本发明的范围应当由所附的权利要求书及其任何等价物来确定。
Claims (17)
1.一种用于检测测试样品中被分析物的存在或量的侧流测定装置,所述侧流测定装置包括多孔膜,所述多孔膜与芯吸垫连通,所述多孔膜限定了:
沉积有含有被分析物的样品的样品施加区;和
固定有第一发色体的检测区,所述第一发色体经构建以与所述被分析物或二次触发剂或来自被分析物和触发剂生成剂的反应产物起化学反应以产生视觉上可觉察的信号。
2.权利要求1的侧流测定装置,所述装置还包括在所述样品施加区和所述检测区之间的触发剂生成区,所述被分析物与材料于触发剂生成区中起反应以产生过氧化氢。
3.权利要求1的侧流测定装置,所述装置还包括经构建以与所述被分析物起化学反应以产生视觉上可觉察的信号的第二发色体。
4.权利要求3的侧流测定装置,所述装置还包括经构建以与所述被分析物起化学反应以产生视觉上可觉察的信号的第三发色体。
5.权利要求1的侧流测定装置,所述装置还包括具有经构建以在不产生视觉上可觉察的信号的情况下与所述被分析物起化学反应的清除材料的清除区。
6.权利要求1的测定装置,其中所述发色体为芳基甲烷。
7.权利要求6的测定装置,其中所述芳基甲烷选自二芳基甲烷和三芳基甲烷。
9.权利要求8的测定装置,其中所述芳基中的至少一个为氨基取代的芳基、羟基取代的芳基、羧基取代的芳基、磺酸基取代的芳基、烷基取代的芳基、羰基取代的芳基或其组合。
10.一种用于检测测试样品中被分析物的存在或量的侧流测定装置,所述侧流测定装置包括多孔膜,所述多孔膜与芯吸垫连通,所述多孔膜按顺序限定了:
沉积有含有被分析物的样品的样品施加区;
所述被分析物与材料于其中反应以产生过氧化氢的触发剂生成区;
固定有第一发色体的第一检测区,所述第一发色体经构建以与过氧化氢起化学反应以产生视觉上可觉察的信号;
具有经构建以在不产生视觉上可觉察的信号的情况下与过氧化氢起化学反应的第一清除材料的第一清除区;
固定有第二发色体的第二检测区,所述第二发色体经构建以与过氧化氢起化学反应以产生视觉上可觉察的信号;
具有经构建以在不产生视觉上可觉察的信号的情况下与过氧化氢起化学反应的第二清除材料的第二清除区;和,
固定有第三发色体的第三检测区,所述第三发色体经构建以与过氧化氢起化学反应以产生视觉上可觉察的信号。
11.一种检测测试样品中被分析物的存在与否的方法,所述方法包括:
i)使测定装置与含有一种或多种被分析物的测试样品接触,所述测定装置包括限定了检测区的多孔膜,其中发色体包含在所述检测区内,所述发色体在与所述被分析物或第二触发剂或来自被分析物和触发剂生成剂的反应产物起化学反应时发生颜色改变;和
ii)测定所述检测区中所述发色体的颜色强度,其中所述颜色强度与测试样品中所述被分析物的某一浓度对应。
12.权利要求11的方法,其中所述发色体为芳基甲烷。
14.权利要求13的方法,其中R、R′或R″中的至少一个为氢基取代的芳基、羟基取代的芳基、羧基取代的芳基、烷基取代的芳基、羰基取代的芳基、磺酸基取代的芳基或其组合。
15.权利要求14的方法,其中测试样品自阴道液获得。
16.权利要求14的方法,其中测试样品自伤口渗液获得。
17.权利要求14的方法,其中测试样品自血液获得。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/079,730 | 2005-03-14 | ||
US11/079,730 US7390674B2 (en) | 2005-03-14 | 2005-03-14 | Lateral flow devices using reactive chemistry |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101137905A true CN101137905A (zh) | 2008-03-05 |
Family
ID=36600202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800081002A Pending CN101137905A (zh) | 2005-03-14 | 2006-01-13 | 使用反应化学的侧流装置 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7390674B2 (zh) |
EP (1) | EP1859280B1 (zh) |
JP (1) | JP4979680B2 (zh) |
KR (1) | KR101324839B1 (zh) |
CN (1) | CN101137905A (zh) |
MX (1) | MX2007011311A (zh) |
WO (1) | WO2006098803A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113543882A (zh) * | 2018-12-31 | 2021-10-22 | 本-古里安大学B.G.内盖夫技术和应用公司 | 捕获流测定装置和方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2918460B1 (fr) | 2007-07-02 | 2013-10-04 | Najim Chaibi | Nouveau dispositif permettant l'obtention des resultats des systemes abo,rhesus et autres pherotypes et systemes rares, rai. |
US20090263905A1 (en) * | 2008-04-18 | 2009-10-22 | Kim Scheuringer | Detection test assembly for detecting the presence of a substance in a sample |
US8647451B2 (en) | 2009-06-29 | 2014-02-11 | The Board Of Regents For Oklahoma State University | Nanometric ink for detection of explosives |
US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
US20140178884A1 (en) * | 2011-05-23 | 2014-06-26 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The Univ. Of Nevada, Reno | Method of diagnosing and treating an aspergillus species-associated condition |
KR101193051B1 (ko) * | 2011-08-25 | 2012-10-22 | 한국과학기술연구원 | 항균필터 성능 평가장치 및 방법 |
WO2013036913A1 (en) | 2011-09-08 | 2013-03-14 | Nexus Dx, Inc. | A multilevel analyte assay |
CN110824177B (zh) * | 2019-09-11 | 2021-06-11 | 润和生物医药科技(汕头)有限公司 | 一种快速检测试纸及其制备方法和应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE224950C (zh) | ||||
US4299916A (en) * | 1979-12-26 | 1981-11-10 | Syva Company | Preferential signal production on a surface in immunoassays |
US4391904A (en) * | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
DD224950A1 (de) * | 1983-12-15 | 1985-07-17 | Adw Ddr | Teststreifen zur bestimmung von h tief 2 o tief 2 bzw. h tief 2 o tief 2-bildenden stoffgemischen |
US4999285A (en) * | 1984-11-15 | 1991-03-12 | Syntex (U.S.A.) Inc. | Chromatographic cassette |
JPS61126471A (ja) * | 1984-11-26 | 1986-06-13 | Konishiroku Photo Ind Co Ltd | 抗原の乾式分析素子 |
JPS6279362A (ja) * | 1985-10-02 | 1987-04-11 | Fuji Photo Film Co Ltd | 酵素活性測定に用いる分析要素 |
DE3620817A1 (de) * | 1986-06-21 | 1987-12-23 | Boehringer Mannheim Gmbh | Verfahren zur spezifischen bestimmung des serumfructosamingehalts sowie hierfuer geeignetes reagenzgemisch |
US4973549A (en) | 1987-06-22 | 1990-11-27 | Chemtrak Corporation | Quantitative diagnostic assay employing signal producing agent bound to support and measuring migration distance of detectable signal |
US4981786A (en) * | 1987-09-04 | 1991-01-01 | Syntex (U.S.A.) Inc. | Multiple port assay device |
EP0339331A3 (de) | 1988-04-29 | 1990-09-19 | ARZNEIMITTELWERK DRESDEN GmbH | Teststreifen zur Bestimmung von Harnstoff und seine Anwendung |
US5620863A (en) | 1989-08-28 | 1997-04-15 | Lifescan, Inc. | Blood glucose strip having reduced side reactions |
US5252496A (en) * | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
JPH053799A (ja) * | 1990-12-21 | 1993-01-14 | Rohto Pharmaceut Co Ltd | 尿中ブドウ糖検査用試験紙 |
US6060256A (en) | 1997-12-16 | 2000-05-09 | Kimberly-Clark Worldwide, Inc. | Optical diffraction biosensor |
DE19845771C2 (de) | 1998-09-22 | 2002-10-31 | Felix Levine | Teststreifen zur Glucosebestimmung in Flüssigkeiten |
US6350543B2 (en) | 1999-12-29 | 2002-02-26 | Kimberly-Clark Worldwide, Inc. | Manganese-rich quaternary metal oxide materials as cathodes for lithium-ion and lithium-ion polymer batteries |
US6673630B2 (en) | 2000-02-23 | 2004-01-06 | Bayer Corporation | Method and apparatus for producing visual results using colorimetric strips |
US6797481B1 (en) * | 2000-10-17 | 2004-09-28 | Dade Behring Marburg Gmbh | Simultaneous screening of multiple analytes |
US20030045003A1 (en) | 2001-07-20 | 2003-03-06 | Smith Jack V. | Method for detection of the adulterant urine luckTM in urine using liquid chemistry, dry chemistry test pads, and lateral flow |
JP2003057240A (ja) * | 2001-08-09 | 2003-02-26 | Nitto Denko Corp | 免疫測定法 |
US20030235923A1 (en) | 2002-06-21 | 2003-12-25 | Jurik Franklin A. | Acceptance testing method for sets of multiple colored workpieces |
US20050191704A1 (en) * | 2004-03-01 | 2005-09-01 | Kimberly-Clark Worldwide, Inc. | Assay devices utilizing chemichromic dyes |
-
2005
- 2005-03-14 US US11/079,730 patent/US7390674B2/en not_active Expired - Fee Related
-
2006
- 2006-01-13 CN CNA2006800081002A patent/CN101137905A/zh active Pending
- 2006-01-13 JP JP2008501871A patent/JP4979680B2/ja not_active Expired - Fee Related
- 2006-01-13 MX MX2007011311A patent/MX2007011311A/es active IP Right Grant
- 2006-01-13 WO PCT/US2006/001418 patent/WO2006098803A1/en active Application Filing
- 2006-01-13 KR KR1020077020999A patent/KR101324839B1/ko not_active IP Right Cessation
- 2006-01-13 EP EP06718486A patent/EP1859280B1/en not_active Not-in-force
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113543882A (zh) * | 2018-12-31 | 2021-10-22 | 本-古里安大学B.G.内盖夫技术和应用公司 | 捕获流测定装置和方法 |
Also Published As
Publication number | Publication date |
---|---|
MX2007011311A (es) | 2007-10-08 |
JP4979680B2 (ja) | 2012-07-18 |
KR20070115958A (ko) | 2007-12-06 |
WO2006098803A1 (en) | 2006-09-21 |
US20060205087A1 (en) | 2006-09-14 |
EP1859280B1 (en) | 2011-05-25 |
EP1859280A1 (en) | 2007-11-28 |
JP2008533488A (ja) | 2008-08-21 |
US7390674B2 (en) | 2008-06-24 |
KR101324839B1 (ko) | 2013-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101137905A (zh) | 使用反应化学的侧流装置 | |
US8865088B2 (en) | Liquid sample assay device | |
DE3851772T2 (de) | Einrichtung für Immunoassay. | |
JP3114528U (ja) | 液体サンプルの分析装置 | |
JP4351358B2 (ja) | 改善された免疫クロマトグラフィー分析 | |
EP0296826B1 (en) | Diagnostic assay employing signal producing agent on support | |
CN103954751B (zh) | 纸基微流控免疫传感器芯片和现场及时检测免疫分析平台 | |
TW507076B (en) | Improved reagent test strip for optically determining blood glucose concentration | |
AU2005225088B8 (en) | Combination assay for alcohol and drugs of abuse | |
NZ200431A (en) | Specimen test slide and method of testing for occult blood | |
US11604189B2 (en) | Detection device capable of visual test results | |
US8153444B2 (en) | Immuno gold lateral flow assay | |
US9075048B2 (en) | Assay apparatus and its control method and reaction container for assay | |
JP3859027B2 (ja) | 乳頭分泌液中の特定物質の測定方法 | |
CN212031502U (zh) | 具有指示区域的侧流试剂条及包括该侧流试剂条的检测卡 | |
US20150024514A1 (en) | Method and device for detecting analytes | |
KR100254108B1 (ko) | 금콜로이드면역측정법 | |
JP2009002822A (ja) | イムノクロマトグラフィー測定法及びキット | |
CN215415460U (zh) | 一种快速检测试纸条及快速检测卡 | |
JP2005083927A (ja) | 免疫測定具 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080305 |